Coverage
Orion has secured an exclusive license for an experimental cancer antibody from Abzena, the latest in a series of deals to strengthen its oncology pipeline following a recent clinical trial failure.
Finnish drugmaker Orion Corp. said Tuesday its experimental insomnia drug failed a mid-stage clinical trial, days after investment giant BlackRock Inc. cut its stake in the company.
Orion and its partner Bayer have secured European Union approval for an expanded use of their blockbuster prostate cancer drug, Nubeqa, the latest in a series of regulatory wins for the treatment.
Orion Corp. reported a 59% surge in second-quarter operating profit, driven by strong sales and royalty income from its blockbuster prostate cancer drug, Nubeqa.
Finnish drugmaker Orion on Wednesday raised its full-year 2025 forecast, citing stronger-than-expected product sales and royalty income.
A European Medicines Agency panel recommended expanding the use of a prostate cancer drug from Orion and its partner Bayer, moving the blockbuster treatment a step closer to a third approval in the region.
Filings
| Filing | Date |
|---|---|
| Board of Directors and Auditors of Krona | 14 Mar 2003 |
| Marianne Dicander Alexandersson appointe | 12 Mar 2003 |
| Orion Pharma taking actions to improve | 10 Mar 2003 |
| Orion discontinues deramciclane studies | 18 Feb 2003 |
| ORION GROUP FINANCIAL STATEMENTS BULLETI | 18 Feb 2003 |
| BOARD OF DIRECTORS OF ORION PROPOSES MER | 18 Feb 2003 |
| ORION CORPORATION SHARE REPURCHASE 29.01 | 29 Jan 2003 |
| ORION CORPORATION SHARE REPURCHASE 28.01 | 28 Jan 2003 |
| ORION CORPORATION SHARE REPURCHASE 27.01 | 27 Jan 2003 |
| ORION CORPORATION SHARE REPURCHASE 24.01 | 24 Jan 2003 |
| ORION CORPORATION SHARE REPURCHASE 23.01 | 23 Jan 2003 |
| ORION CORPORATION SHARE REPURCHASE 22.01 | 22 Jan 2003 |